HRP20192237T1 - Derivati aminohidrotiazina kondenzirani s tetrahidrofuranom, korisni u liječenju alzheimerove bolesti - Google Patents
Derivati aminohidrotiazina kondenzirani s tetrahidrofuranom, korisni u liječenju alzheimerove bolesti Download PDFInfo
- Publication number
- HRP20192237T1 HRP20192237T1 HRP20192237TT HRP20192237T HRP20192237T1 HR P20192237 T1 HRP20192237 T1 HR P20192237T1 HR P20192237T T HRP20192237T T HR P20192237TT HR P20192237 T HRP20192237 T HR P20192237T HR P20192237 T1 HRP20192237 T1 HR P20192237T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- salt
- pharmaceutically acceptable
- tetrahydrofuro
- thiazin
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims 3
- 150000003839 salts Chemical class 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- JJADJMODPHLYCB-DAESXHAQSA-N N-[3-[(4aS,5S,7aS)-2-amino-5-(1,1-difluoroethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound NC=1SC[C@H]2[C@@](N=1)(CO[C@@H]2C(C)(F)F)C=1C=C(C=CC=1F)NC(=O)C1=NC=C(C=C1)C#N JJADJMODPHLYCB-DAESXHAQSA-N 0.000 claims 2
- VZSPTGDSXXGQKM-OKLLSCIYSA-N N-[3-[(4aS,5S,7aS)-2-amino-5-(1,1-difluoroethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide 4-methylbenzenesulfonic acid Chemical compound Cc1ccc(cc1)S(O)(=O)=O.CC(F)(F)[C@H]1OC[C@@]2(N=C(N)SC[C@H]12)c1cc(NC(=O)c2ccc(cn2)C#N)ccc1F VZSPTGDSXXGQKM-OKLLSCIYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- MXBLXZCJEGMURG-OKLLSCIYSA-N N-[3-[(4aS,5S,7aS)-2-amino-5-(1,1-difluoroethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CC(F)(F)[C@H]1OC[C@@]2(N=C(N)SC[C@H]12)c1cc(NC(=O)c2ccc(cn2)C#N)ccc1F MXBLXZCJEGMURG-OKLLSCIYSA-N 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
- C07C309/31—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups by alkyl groups containing at least three carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Claims (17)
1. Spoj, naznačen time što je spoj formule:
,
ili njegova farmaceutski prihvatljiva sol.
2. Spoj, ili njegova sol, u skladu s patentnim zahtjevom 1, naznačen time što je spoj:
.
3. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što je spoj:
.
4. Sol u skladu s patentnim zahtjevom 3, naznačena time što je:
.
5. Sol u skladu s patentnim zahtjevom 3, naznačena time što je:
.
6. Sol u skladu s patentnim zahtjevom 3, naznačena time što je:
.
7. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je spoj N-[3-[(4aS,5S,7aS)-2-amino-5-(1,1-difluoretil)-4,4a,5,7-tetrahidrofuro[3,4-d][1,3]tiazin-7a-il]-4-fluorfenil]-5-cijanopiridin-2-karboksamid.
8. Spoj u skladu s patentnim zahtjevom 3, naznačena time što je N-[3-[(4aS,5S,7aS)-2-amino-5-(1,1-difluoretil)-4,4a,5,7-tetrahidrofuro[3,4-d][1,3]tiazin-7a-il]-4-fluorfenil]-5-cijanopiridin-2-karboksamid.
9. Sol u skladu s patentnim zahtjevom 4, naznačena time što je N-[3-[(4aS,5S,7aS)-2-amino-5-(1,1-difluoretil)-4,4a,5,7-tetrahidrofuro[3,4-d][1,3]tiazin-7a-il]-4-fluorfenil]-5-cijanopiridin-2-karboksamid-4-metilbenzensulfonat.
10. Sol u skladu s patentnim zahtjevom 5, naznačena time što je N-[3-[(4aS,5S,7aS)-2-Amino-5-(1,1-difluoretil)-4,4a,5,7-tetrahidrofuro[3,4-d][1,3]tiazin-7a-il]-4-fluorfenil]-5-cijanopiridin-2-karboksamid-4-metilbenzensulfonat hemihidrat.
11. Sol u skladu s patentnim zahtjevom 10, naznačena time što ima značajan maksimum u spektru difrakcije rendgenskih zraka, pod kutom difrakcije 2θ od 6,8° u kombinaciji s jednim ili više maksimuma koje se bira iz skupine koju čine 19,7°, 14,9°, i 10,3°; s tolerancijom za kutove difrakcije od 0,2 stupnjeva.
12. Sol u skladu s patentnim zahtjevom 6, naznačena time što je N-[3-[(4aS,5S,7aS)-2-amino-5-(1,1-difluoretil)-4,4a,5,7-tetrahidrofuro[3,4-d][1,3]tiazin-7a-il]-4-fluorfenil]-5-cijanopiridin-2-karboksamid-metansulfonat.
13. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time što je namijenjen upotrebi u terapiji.
14. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time što je namijenjen upotrebi u liječenju Alzheimerove bolesti.
15. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time što je namijenjen upotrebi u liječenju napredovanja blagog kognitivnog poremećaja do Alzheimerove bolesti.
16. Farmaceutski pripravak, naznačen time što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol, u skladu s bilo kojim od patentnih zahtjeva 1-12, kao i jedan ili više farmaceutski prihvatljivih nosača, razrjeđivača ili pomoćnih tvari.
17. Postupak priprave farmaceutskog pripravka, naznačen time što se sastoji u miješanju spoja, ili njegove farmaceutski prihvatljive soli, u skladu s bilo kojim od patentnih zahtjeva 1-12 s jednim ili više farmaceutski prihvatljivih nosača, razrjeđivača ili pomoćnih tvari.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154242P | 2015-04-29 | 2015-04-29 | |
| EP16719728.4A EP3288949B1 (en) | 2015-04-29 | 2016-04-22 | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease |
| PCT/US2016/028896 WO2016176118A1 (en) | 2015-04-29 | 2016-04-22 | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192237T1 true HRP20192237T1 (hr) | 2020-03-06 |
Family
ID=55861291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192237TT HRP20192237T1 (hr) | 2015-04-29 | 2019-12-12 | Derivati aminohidrotiazina kondenzirani s tetrahidrofuranom, korisni u liječenju alzheimerove bolesti |
Country Status (40)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR103680A1 (es) * | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
| AR110470A1 (es) * | 2016-10-21 | 2019-04-03 | Lilly Co Eli | Terapia de combinación para tratar la enfermedad de alzheimer |
| US11559528B2 (en) * | 2019-09-05 | 2023-01-24 | The Cleveland Clinic Foundation | BACE1 inhibition for the treatment of cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1896478B1 (en) | 2005-06-14 | 2014-05-21 | Merck Sharp & Dohme Corp. | Aspartyl protease inhibitors |
| US8158620B2 (en) * | 2008-01-18 | 2012-04-17 | Eisai R&D Management Co., Ltd. | Fused aminodihydrothiazine derivatives |
| NZ589590A (en) | 2008-06-13 | 2012-05-25 | Shionogi & Co | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
| ES2539859T3 (es) | 2008-09-30 | 2015-07-06 | Eisai R&D Management Co., Ltd. | Nuevo derivado de aminodihidrotiazina condensado |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| WO2011071057A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
| GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101140D0 (en) * | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| WO2012147762A1 (ja) * | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | ピリジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| AR086539A1 (es) | 2011-05-24 | 2014-01-08 | Bristol Myers Squibb Co | COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE |
| WO2014015125A1 (en) | 2012-07-19 | 2014-01-23 | Eisai R&D Management Co., Ltd. | Fused aminodihydrothiazine derivative salts and uses thereof |
| JP2014101354A (ja) * | 2012-10-24 | 2014-06-05 | Shionogi & Co Ltd | Ｂａｃｅ１阻害作用を有するオキサジン誘導体 |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
| AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
| TWI675034B (zh) | 2016-05-20 | 2019-10-21 | 美商美國禮來大藥廠 | 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性ＢＡＣＥ１抑制劑之用途 |
| JP2019524788A (ja) | 2016-08-11 | 2019-09-05 | イーライ リリー アンド カンパニー | アミノチアジンおよびｂａｃｅ１阻害剤としてのそれらの使用 |
-
2016
- 2016-04-13 AR ARP160100992A patent/AR104241A1/es unknown
- 2016-04-15 TW TW105111913A patent/TWI619719B/zh not_active IP Right Cessation
- 2016-04-22 CR CR20170433A patent/CR20170433A/es unknown
- 2016-04-22 ME MEP-2019-353A patent/ME03660B/me unknown
- 2016-04-22 SG SG11201708003WA patent/SG11201708003WA/en unknown
- 2016-04-22 RS RS20191653A patent/RS59729B1/sr unknown
- 2016-04-22 PT PT167197284T patent/PT3288949T/pt unknown
- 2016-04-22 SI SI201630511T patent/SI3288949T1/sl unknown
- 2016-04-22 US US15/135,580 patent/US10011610B2/en active Active
- 2016-04-22 MY MYPI2017704013A patent/MY180727A/en unknown
- 2016-04-22 PE PE2017001998A patent/PE20180048A1/es unknown
- 2016-04-22 PL PL16719728T patent/PL3288949T3/pl unknown
- 2016-04-22 ES ES16719728T patent/ES2765646T3/es active Active
- 2016-04-22 BR BR112017020180-1A patent/BR112017020180A2/pt not_active Application Discontinuation
- 2016-04-22 AU AU2016254980A patent/AU2016254980B2/en not_active Ceased
- 2016-04-22 DK DK16719728.4T patent/DK3288949T3/da active
- 2016-04-22 CA CA2981091A patent/CA2981091A1/en active Pending
- 2016-04-22 NZ NZ735249A patent/NZ735249A/en not_active IP Right Cessation
- 2016-04-22 CN CN201680024772.6A patent/CN107531728B/zh active Active
- 2016-04-22 TN TNP/2017/000448A patent/TN2017000448A1/en unknown
- 2016-04-22 KR KR1020177030721A patent/KR101979534B1/ko active IP Right Grant
- 2016-04-22 JP JP2016567244A patent/JP2017515831A/ja not_active Withdrawn
- 2016-04-22 MA MA41975A patent/MA41975B1/fr unknown
- 2016-04-22 HU HUE16719728A patent/HUE047160T2/hu unknown
- 2016-04-22 WO PCT/US2016/028896 patent/WO2016176118A1/en active Application Filing
- 2016-04-22 EP EP16719728.4A patent/EP3288949B1/en active Active
- 2016-04-22 MD MDE20180225T patent/MD3288949T2/ro unknown
- 2016-04-22 EA EA201792109A patent/EA032293B1/ru not_active IP Right Cessation
- 2016-04-22 MX MX2017013694A patent/MX2017013694A/es unknown
-
2017
- 2017-08-31 IL IL254252A patent/IL254252A0/en unknown
- 2017-10-17 SV SV2017005547A patent/SV2017005547A/es unknown
- 2017-10-17 DO DO2017000240A patent/DOP2017000240A/es unknown
- 2017-10-18 CL CL2017002651A patent/CL2017002651A1/es unknown
- 2017-10-20 CO CONC2017/0010725A patent/CO2017010725A2/es unknown
- 2017-10-26 PH PH12017501955A patent/PH12017501955A1/en unknown
- 2017-10-27 EC ECIEPI201771769A patent/ECSP17071769A/es unknown
- 2017-10-27 GT GT201700227A patent/GT201700227A/es unknown
-
2018
- 2018-03-08 HK HK18103304.5A patent/HK1243709A1/zh unknown
- 2018-03-13 JP JP2018045585A patent/JP6777668B2/ja active Active
-
2019
- 2019-12-04 CY CY20191101285T patent/CY1122375T1/el unknown
- 2019-12-12 HR HRP20192237TT patent/HRP20192237T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192237T1 (hr) | Derivati aminohidrotiazina kondenzirani s tetrahidrofuranom, korisni u liječenju alzheimerove bolesti | |
| HRP20211011T1 (hr) | N-[4-fluor-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oksadiazol-3-il)metoksi]-1-piperidil]metil]tiazol-2-il]acetamid kao inhibitor oga | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| JOP20190077A1 (ar) | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret | |
| EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
| HRP20190842T1 (hr) | Kristalni oblici 2-((4s)-6-(4-hlorofenil)-1-metil-4h-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| EP4252848A3 (en) | Oxysterols and methods of use thereof | |
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| PH12016500359A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
| WO2015132799A3 (en) | Heterocyclic compounds | |
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| SA519402180B1 (ar) | مركب حلقي غير متجانس جديد، وطريقة تحضيره، وتركيبة صيدلانية تشتمل على نفس المركب | |
| PH12016501651B1 (en) | Triazine compound and use thereof for medical purposes | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| HRP20211013T1 (hr) | Antagonisti receptora cgrp | |
| HRP20192235T1 (hr) | SPOJEVI KORISNI ZA INHIBITIRANJE ROR-γ-T | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| WO2015171526A3 (en) | Tricyclic pyrazolopyridine compounds | |
| EA201600636A1 (ru) | 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды | |
| HRP20192240T1 (hr) | TOSILATNA SOL N-[3-[(4aR,7aS)-2-AMINO-6-(5-FLUOROPIRIMIDIN-2-IL)-4,4a,5,7-TETRAHIDROPIROLO[3,4-d][1,3]TIAZIN-7a-IL]-4-FLUOROFENIL]-5-METOKSIPIRAZIN-2-KARBOKSAMIDA | |
| HRP20201187T1 (hr) | Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 | |
| HRP20190961T1 (hr) | Derivat tetrahidropirolo[3,4-d][1,3]tiazina kao inhibitor bace | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists |